Last reviewed · How we verify

Cook MyoSite — Portfolio Competitive Intelligence Brief

Cook MyoSite pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
AMDC-USR (iltamiocel) AMDC-USR (iltamiocel) phase 3 Autologous cell therapy Cardiovascular

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. GC Cell Corporation · 1 shared drug class
  2. Seoul National University Bundang Hospital · 1 shared drug class
  3. Sewon Cellontech Co., Ltd. · 1 shared drug class
  4. StemCyte, Inc. · 1 shared drug class
  5. Tetec AG · 1 shared drug class
  6. TiGenix n.v. · 1 shared drug class
  7. UnicoCell Biomed CO. LTD · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Cook MyoSite:

Cite this brief

Drug Landscape (2026). Cook MyoSite — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cook-myosite. Accessed 2026-06-09.

Related